Liver Cancer Therapy Innovations

Hepatocellular carcinoma (HCC), the most common form of liver cancer, is now being treated with powerful combination therapies involving immunotherapy and TKIs.

Top 2025 Strategies:

  • Atezolizumab + Bevacizumab: Improved survival in advanced HCC

  • Cabozantinib + Durvalumab: Promising TKI + checkpoint inhibitor combo

  • Microbiota modulation: Gut flora influences immune response

2025 Insight:

“Combination therapy with Atezolizumab and Bevacizumab extended median overall survival to 19.2 months vs. 13.4 months with Sorafenib.”
Source: Journal of Hepatology, 2025

Section

Best Candidates:

  • Advanced-stage HCC patients

  • Those unfit for chemotherapy

  • Patients eligible for VEGF and checkpoint inhibitors

    References:

  • Combination Immunotherapy in Advanced HCC – Journal of Hepatology, 2025

  • Microbiome’s Role in Liver Cancer Response to Immunotherapy – Nature Gastroenterology, 2025

  • Tyrosine Kinase Inhibitor Combinations in HCC – ESMO Liver Oncology Report, 2025